Evaluating a critically ill patient with metabolic acidosis: the ifosfamide paradigm.
Lehrich
R W
RW
Franz Volhard Clinic, Medical Faculty of the Charité, Humboldt University of Berlin, Germany.
Moll
S
S
Luft
F C
FC
D000138:Acidosis / Q000097:blood / Q000139:chemically induced* / Q000652:urine; D000141:Acidosis, Renal Tubular / Q000097:blood / Q000139:chemically induced* / Q000652:urine; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002245:Carbon Dioxide / Q000097:blood; D003131:Combined Modality Therapy; D003404:Creatinine / Q000097:blood; D016638:Critical Illness; D004317:Doxorubicin / Q000008:administration & dosage; D004573:Electrolytes / Q000097:blood / Q000652:urine; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009503:Neutropenia / Q000139:chemically induced; D010100:Oxygen / Q000097:blood; D011859:Radiography; D013584:Sarcoma, Synovial / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery / Q000628:therapy; D014883:Water-Electrolyte Imbalance / Q000097:blood / Q000139:chemically induced
D004573:Electrolytes; D002245:Carbon Dioxide; D004317:Doxorubicin; D003404:Creatinine; D010100:Oxygen; D007069:Ifosfamide